IMV Preps for 2 Phase 2B Trials

IMV, the Dartmouth-based drug discovery company, is planning two Phase 2B trials in the coming months that it hopes will be key steps in bringing its lead compound DPX-Survivac to the market in a few years.
Though its shares have been languishing lately, the company has added key staff members after reporting good results on clinical trials for Survivac in December and is proceeding with further